Carmot Therapeutics Stock

carmot-therapeutics.usHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $372.31MM

Carmot Therapeutics is focused on the discovery and development of disease-modifying therapies for patients living with metabolic diseases and cancer. Carmot applies Chemotype Evolution (CE), a pioneering drug discovery platform, in combination with unique biological expertise to identify innovative and superior therapeutics.

Register To Buy and Sell Shares

For more details on financing and valuation for Carmot Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Carmot Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Carmot Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Heather Turner
Chief Executive Office
Manu Cakravarthy, MD, PhD
Chief Medical & Scienctific
Michael Gray
Chief Operating Officer

Frequently Asked Questions About Carmot Therapeutics’ Stock

Can you buy Carmot Therapeutics’ stock?
Carmot Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Carmot Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Carmot Therapeutics’ stock?
Yes, you can sell stock of a private company like Carmot Therapeutics. Forge can help you sell your Carmot Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Carmot Therapeutics’ stock price?
Carmot Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Carmot Therapeutics’ private market stock price with Forge Data.
What is Carmot Therapeutics’ stock ticker symbol?
Carmot Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Schroders Capital Global Innovation’s Carmot Therapeutics sold to Roche
Schroders Capital Global Innovation (INOV) has announced that its portfolio company Carmot Therapeutics Inc., a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, entered into a definitive agreement to be acquired by Roche, on 3 December 2023. Roche is acquiring Carmot at a purchase price of US$2.7 billion upfront with the potential for US$400 million in milestone payments. The agreement is expected to close in the first quarter of 2024, subject to customary closing conditions and required regulatory approvals. INOV says that full details of its profit on the sale will be released in due course.
Carmot Readies IPO to Seize Bulging Obesity and Diabetes Market
Gloomy clouds may still hang thick over the initial public offering (IPO) market, but some companies are still wading into the listing abyss. Investors seeking a new biopharma play have a new deal to size up. On November 20, Carmot Therapeutics filed its paperwork with the Securities and Exchange Commission (SEC) for its debut in public markets. The firm has not yet released price details for the deal; instead, it is citing the placeholder sum of $100 million in its submitted documentation. The company hopes to list its shares on Nasdaq “as soon as practicable after this registration” under the ticker “CRMO.”
Carmot Therapeutics Raises $150M in Series E Equity Financing
Carmot Therapeutics, a Berkeley, CA-based clinical-stage biotechnology company, raised $150M in Series E funding. The round was led by Deep Track Capital with participation from 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, RA Capital Management, Millennium Management, TCGX, The Column Group, Venrock Healthcare Capital Partners and Willett Advisors.
Updated on: Apr 13, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.